TherapeuticsMD: Jumps after UK, Belgium approve hormone therapy

TherapeuticsMD

09/04/2021 10:40

** Shares of women's healthcare co  TXMD.O  jump 21.2% to
$1.60 premarket, touching their 50-day moving avg price
    ** TXMD is among most heavily traded stocks across U.S.
exchanges before the bell
    ** Says hormone therapy BIJUVE received regulatory approval
in UK and Belgium  urn:newsml:reuters.com:*:nBwbmDrJQa
    ** Under license agreement with pharma co Theramex, TXMD
will receive a milestone fee for the regulatory approval of drug
in certain European markets, sales milestone fees and royalties
    ** The drug is approved in the U.S. to treat hot flashes due
to menopause in women with a uterus
    ** TXMD has gained 9.1% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))